Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s third positive Phase 3 readout for DT120 ODT, following the positive Emerge results in major depressive disorder (MDD) announced in June and the positive Voyage results in GAD announced in August.
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s third positive Phase 3 readout for DT120 ODT, following the positive Emerge results in major depressive disorder (MDD) announced in June and the positive Voyage results in GAD announced in August.
Tech-Enabled Rural Health Care Leader Hopscotch Primary Care Announces $53 Million in Latest Funding Round
Hopscotch Primary Care, a technology-enabled primary care model that serves patients in rural communities, has raised $53 million in its series D financing. Founded in 2021, the company serves more than 15,000 patients across the Southeastern United States, with its largest concentration in rural Western North Carolina. Hopscotch will use the new funding to deepen access across the region, expand into new rural markets, and continue to scale its technology-powered operations. Lead investors in the round include 8VC and Town Hall Ventures, with participation from existing investors including aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures. New investors in the round include the Autism Impact Fund (AIF), John Doerr, Chairman of Kleiner Perkins, and Dr. Richard Merkin, Founder of Heritage Provider Network, and the Leon Levine Foundation.
Hopscotch Primary Care, a technology-enabled primary care model that serves patients in rural communities, has raised $53 million in its series D financing. Founded in 2021, the company serves more than 15,000 patients across the Southeastern United States, with its largest concentration in rural Western North Carolina. Hopscotch will use the new funding to deepen access across the region, expand into new rural markets, and continue to scale its technology-powered operations. Lead investors in the round include 8VC and Town Hall Ventures, with participation from existing investors including aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures. New investors in the round include the Autism Impact Fund (AIF), John Doerr, Chairman of Kleiner Perkins, and Dr. Richard Merkin, Founder of Heritage Provider Network, and the Leon Levine Foundation.
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy
Investors are pumping more money into one of the microbiome field’s longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year. Cambridge, MA-based Vedanta Biosciences said Thursday its two main existing investors, AMR Action Fund and BNP Paribas Asset Management Alts, contributed an additional $40 million. It got another $20 million under its existing contract with BARDA.
Investors are pumping more money into one of the microbiome field’s longest-standing biotechs to push it toward a Phase 3 readout in C. difficile next year. Cambridge, MA-based Vedanta Biosciences said Thursday its two main existing investors, AMR Action Fund and BNP Paribas Asset Management Alts, contributed an additional $40 million. It got another $20 million under its existing contract with BARDA.
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disease.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disease.
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
Mighty Therapeutics Holdings Inc., a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The Company has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences and healthcare, to provide a credit facility of up to $125 million, including an initial $30 million tranche. The Company has also held an initial closing of its Series B financing, in which founding investor Morningside has invested $25 million.
Mighty Therapeutics Holdings Inc., a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The Company has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences and healthcare, to provide a credit facility of up to $125 million, including an initial $30 million tranche. The Company has also held an initial closing of its Series B financing, in which founding investor Morningside has invested $25 million.
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s third positive Phase 3 readout for DT120 ODT, following the positive Emerge results in major depressive disorder (MDD) announced in June and the positive Voyage results in GAD announced in August.
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s third positive Phase 3 readout for DT120 ODT, following the positive Emerge results in major depressive disorder (MDD) announced in June and the positive Voyage results in GAD announced in August.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD. Building on robust preclinical data from both in vitro and in vivo studies, the Company has exercised its option with JCR Pharmaceuticals (JCR) as part of its previously signed agreement and will advance both candidates combining Acumen’s AβO-selective antibody expertise and JCR’s validated transferrin-receptor-targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo®. By selecting these two candidates, the Company is expanding its optionality by nominating a bispecific antibody derived from sabirnetug as well as one based on a novel, next generation AβO-selective antibody with differentiated properties, known as ACU234.
Mighty Therapeutics Holdings Inc., a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The Company has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences and healthcare, to provide a credit facility of up to $125 million, including an initial $30 million tranche. The Company has also held an initial closing of its Series B financing, in which founding investor Morningside has invested $25 million.
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an agreement with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150 million including an initial $50 million tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028. The Company also announced progress across its pipeline, including updated timelines for all ongoing trials of Descartes-08, an autologous anti-B cell maturation antigen (BCMA) mRNA chimeric antigen receptor T-cell therapy (CAR-T).
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an agreement with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150 million including an initial $50 million tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028. The Company also announced progress across its pipeline, including updated timelines for all ongoing trials of Descartes-08, an autologous anti-B cell maturation antigen (BCMA) mRNA chimeric antigen receptor T-cell therapy (CAR-T).
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the United States, representing patients who do not respond adequately to current antidepressant therapies.
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the United States, representing patients who do not respond adequately to current antidepressant therapies.
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization.
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization.
Trice Medical Launches Tenex® 2nd Generation Ultrasonic System, Expanding Minimally Invasive Treatment For Chronic Tendon Paid
Trice Medical announced nationwide commercial availability of the FDA-cleared Tenex® 2nd Generation System, building on the proven Tenex Health TX® platform that has been used in more than 240,000 procedures. The Tenex 2nd Generation System is an advanced platform designed to expand minimally invasive ultrasonic procedures for the treatment of chronic tendon disease and other musculoskeletal conditions, including calcific deposits, bone spurs, and diabetic foot ulcers.
Trice Medical announced nationwide commercial availability of the FDA-cleared Tenex® 2nd Generation System, building on the proven Tenex Health TX® platform that has been used in more than 240,000 procedures. The Tenex 2nd Generation System is an advanced platform designed to expand minimally invasive ultrasonic procedures for the treatment of chronic tendon disease and other musculoskeletal conditions, including calcific deposits, bone spurs, and diabetic foot ulcers.
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large biotech dedicated investor.
Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large biotech dedicated investor.
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.
Honest Health Raises $140 Million to Advance Value-Based Care for Health Systems
Honest Health today announced a $140 million capital raise, led by NewSpring Healthcare, a sector-focused strategy of NewSpring dedicated to partnering with innovative healthcare companies. The investment reflects growing demand for Honest Health's health system-focused approach and its track record of helping organizations execute successfully in value-based payment models.
Honest Health today announced a $140 million capital raise, led by NewSpring Healthcare, a sector-focused strategy of NewSpring dedicated to partnering with innovative healthcare companies. The investment reflects growing demand for Honest Health's health system-focused approach and its track record of helping organizations execute successfully in value-based payment models.
Kandu trial highlights positive outcomes with IpsiHand BCI system
Kandu Health announced positive results from the first randomized controlled trial of its brain-computer interface (BCI) therapy. The trial evaluated its FDA-cleared, non-invasive IpsiHand BCI system in chronic stroke survivors. It detailed outcomes from a post-market randomized controlled study evaluating the clinical performance of IpsiHand. IpsiHand received FDA clearance in 2021 as a breakthrough-designated, 510(k)-cleared device for stroke rehabilitation.
Kandu Health announced positive results from the first randomized controlled trial of its brain-computer interface (BCI) therapy. The trial evaluated its FDA-cleared, non-invasive IpsiHand BCI system in chronic stroke survivors. It detailed outcomes from a post-market randomized controlled study evaluating the clinical performance of IpsiHand. IpsiHand received FDA clearance in 2021 as a breakthrough-designated, 510(k)-cleared device for stroke rehabilitation.
RoundTable Healthcare Partners Invests in Colorscience, a Premium Skincare and Sun Protection Brand
RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced a partnership and investment in Colorescience, Inc. which supports the company’s next phase of innovation and growth.
RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced a partnership and investment in Colorescience, Inc. which supports the company’s next phase of innovation and growth.
Zarminali Pediatrics Raises $110M Series A To Transform American Pediatric Care
Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide integrated primary and specialty care nationwide, today announced a $110M Series A funding round. Healthier Capital led the round, along with participation from existing investor General Catalyst, and new investor K2 HealthVentures.
Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide integrated primary and specialty care nationwide, today announced a $110M Series A funding round. Healthier Capital led the round, along with participation from existing investor General Catalyst, and new investor K2 HealthVentures.
Kandu, Inc. Announces Appointment of Marshal Linder to Board of Directors and Strategic Growth Investment from K2 HealthVentures and Piper Sandler Merchant Bank
Kandu, Inc., a healthcare technology company pioneering integrated stroke recovery solutions for post-stroke care, today announced the appointment of Marshal Linder to its Board of Directors. The company also announced the completion of a strategic growth capital investment from K2 HealthVentures and Piper Sandler Merchant Bank, with Toby AuWerter joining the Board in an observer capacity.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease.